retatrutide clinical trials phase Shows 28% Weight Loss in 80 Weeks Retatrutide Phase 3: TRIUMPH Program

FDA approval requires a complete review of benefits, risks, dosing, safety data, manufacturing quality, and patient use instructions

Patients with strong genetic signals for GLP-1 responsiveness often achieve better sustained results, helping guide whether long-term therapy is likely to work well for your biology

In summary, all the above content indicates that a new therapeutic approach is needed to deal with diseases related to the gut-liver axis

That's what I'm trying to do

Prokopidis K

The precautionary principle suggests delaying GLP-1 initiation until breastfeeding concludes, allowing mothers to focus on nursing without unnecessary medication exposure to infants